News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
323,144 Results
Type
Article (17438)
Company Profile (107)
Press Release (305599)
Multimedia
Podcasts (52)
Webinars (10)
Section
Business (109413)
Career Advice (754)
Deals (19310)
Drug Delivery (74)
Drug Development (41175)
Employer Resources (67)
FDA (7098)
Job Trends (7278)
News (180720)
Policy (16284)
Tag
Academia (641)
Accelerated approval (2)
Adcomms (6)
Allergies (39)
Alliances (25870)
ALS (43)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (56)
Approvals (7138)
Artificial intelligence (131)
Autoimmune disease (14)
Automation (6)
Bankruptcy (182)
Best Places to Work (5280)
BIOSECURE Act (9)
Biosimilars (59)
Biotechnology (48)
Bladder cancer (26)
Brain cancer (18)
Breast cancer (108)
Cancer (812)
Cardiovascular disease (77)
Career advice (659)
Career pathing (14)
CAR-T (45)
Cell therapy (143)
Cervical cancer (5)
Clinical research (34530)
Collaboration (420)
Compensation (180)
Complete response letters (17)
COVID-19 (950)
CRISPR (24)
C-suite (175)
Cystic fibrosis (51)
Data (824)
Denatured (16)
Depression (12)
Diabetes (121)
Diagnostics (1939)
Digital health (4)
Diversity (2)
Diversity, equity & inclusion (18)
Drug discovery (71)
Drug pricing (71)
Drug shortages (15)
Duchenne muscular dystrophy (50)
Earnings (43018)
Editorial (22)
Employer branding (5)
Employer resources (59)
Events (44688)
Executive appointments (523)
FDA (7645)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (322)
Gene editing (50)
Generative AI (9)
Gene therapy (134)
GLP-1 (399)
Government (1675)
Grass and pollen (3)
Guidances (32)
Healthcare (5810)
Huntington's disease (7)
IgA nephropathy (14)
Immunology and inflammation (49)
Indications (14)
Infectious disease (1000)
Inflammatory bowel disease (73)
Inflation Reduction Act (6)
Influenza (19)
Intellectual property (63)
Interviews (95)
IPO (7781)
IRA (31)
Job creations (2223)
Job search strategy (595)
Kidney cancer (7)
Labor market (18)
Layoffs (217)
Leadership (7)
Legal (4054)
Liver cancer (22)
Lung cancer (105)
Lymphoma (64)
Machine learning (2)
Management (20)
Manufacturing (200)
MASH (44)
Medical device (3111)
Medtech (3114)
Mergers & acquisitions (11829)
Metabolic disorders (338)
Multiple sclerosis (28)
NASH (15)
Neurodegenerative disease (35)
Neuropsychiatric disorders (11)
Neuroscience (707)
NextGen: Class of 2025 (2245)
Non-profit (943)
Now hiring (10)
Obesity (182)
Opinion (145)
Ovarian cancer (31)
Pain (60)
Pancreatic cancer (20)
Parkinson's disease (57)
Partnered (8)
Patents (142)
Patient recruitment (40)
Peanut (13)
People (36418)
Pharmaceutical (66)
Pharmacy benefit managers (12)
Phase I (9413)
Phase II (14841)
Phase III (12736)
Pipeline (610)
Policy (82)
Postmarket research (1478)
Preclinical (3728)
Press Release (35)
Prostate cancer (56)
Psychedelics (13)
Radiopharmaceuticals (147)
Rare diseases (208)
Real estate (2952)
Recruiting (28)
Regulatory (11578)
Reports (19)
Research institute (754)
Resumes & cover letters (90)
Rett syndrome (2)
RNA editing (2)
RSV (9)
Schizophrenia (44)
Series A (64)
Series B (23)
Service/supplier (4)
Sickle cell disease (36)
Special edition (9)
Spinal muscular atrophy (86)
Sponsored (13)
Startups (1904)
State (2)
Stomach cancer (4)
Supply chain (42)
Tariffs (33)
The Weekly (34)
Vaccines (223)
Venture capitalists (21)
Weight loss (122)
Women's health (13)
Worklife (6)
Date
Last 7 days (371)
Last 30 days (1070)
Last 365 days (14826)
2025 (4987)
2024 (15977)
2023 (17948)
2022 (24561)
2021 (25419)
2020 (23939)
2019 (18943)
2018 (14862)
2017 (16484)
2016 (15697)
2015 (18338)
2014 (14695)
2013 (12351)
2012 (13340)
2011 (13882)
2010 (12659)
Location
Africa (366)
Alabama (16)
Alaska (3)
Arizona (84)
Arkansas (5)
Asia (23451)
Australia (3130)
California (2337)
Canada (1152)
China (283)
Colorado (132)
Connecticut (92)
Delaware (70)
Europe (46772)
Florida (407)
Georgia (70)
Idaho (12)
Illinois (237)
India (17)
Indiana (199)
Iowa (1)
Japan (103)
Kansas (61)
Kentucky (14)
Louisiana (1)
Maine (7)
Maryland (394)
Massachusetts (1918)
Michigan (49)
Minnesota (126)
Missouri (29)
Montana (21)
Nebraska (12)
Nevada (18)
New Hampshire (20)
New Jersey (983)
New Mexico (13)
New York (682)
North Carolina (482)
North Dakota (2)
Northern California (996)
Ohio (70)
Oklahoma (7)
Oregon (17)
Pennsylvania (568)
Puerto Rico (11)
Rhode Island (14)
South America (597)
South Carolina (2)
Southern California (950)
Tennessee (42)
Texas (356)
United States (9609)
Utah (59)
Virginia (88)
Washington D.C. (35)
Washington State (149)
West Virginia (1)
Wisconsin (18)
323,144 Results for "parnell pharmaceuticals holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering
Parnell Pharmaceuticals Holdings Ltd announced the extension of the backstopped rights offering to raise gross proceeds of approximately US$4.0 million.
January 6, 2023
·
3 min read
Parnell Pharmaceuticals Holdings Ltd Announces Commencement of Rights Offering
Parnell Pharmaceuticals Holdings Ltd commenced its previously announced backstopped rights offering to raise gross proceeds of approximately US$4.0 million.
December 6, 2022
·
4 min read
Deals
Parnell Pharmaceuticals Holdings Ltd Announces Proposed Rights Offering
Parnell Pharmaceuticals Holdings Ltd (OTC Pink ® Open Market: PARNF) (“Parnell”) announced its intention to raise US$4.0 million through a backstopped rights offering at no charge (the “Rights Offering”) for qualifying shareholders of record as of December 6, 2022 (the “Record Date”).
December 1, 2022
·
3 min read
Press Releases
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
April 30, 2025
·
3 min read
Immunology and inflammation
Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis
The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent observation of testicular toxicity in canines given the treatment.
April 25, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Committee Recommends EU Trials of Sarepta’s Elevidys Continue, Day After Holds
One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the death of a U.S. teenager, a data monitoring committee concluded that they should continue unchanged.
April 4, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
February 21, 2025
·
3 min read
Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum
Parnell Pharmaceuticals Holdings Ltd, a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Friday, 15th July 2022 at 8:30 a.m..
June 21, 2022
·
2 min read
Press Releases
Ionis to hold first quarter 2025 financial results webcast
April 16, 2025
·
1 min read
Press Releases
Additional Member for the Board of Directors of Bachem Holding AG
April 3, 2025
·
3 min read
1 of 32,315
Next
